EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Degraders upgraded: the rise of PROTACs in hematological malignancies

Joshua M L Casan iD, John F Seymour iD

Blood · 2024

DOI: 10.1182/blood.2023022993 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, 2024. Verfasst von Joshua M L Casan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Hematologic Neoplasms. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 153 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in hematological malignancies that potentially circumvents many constraints of existing small-molecule inhibitors. Heterobifunctional proteolysis-targeting chimeras (PROTACs) are the leading TPD drug class, with numerous agents now in clinical trials for a range of blood cancers. PROTACs harness the cell-intrinsic protein recycling infrastructure, the ubiquitin-proteasome system, to completely degrade target proteins. Distinct from targeted small-molecule inhibitor therapies, PROTACs can eliminate critical but conventionally “undruggable” targets, overcome resistance mechanisms to small-molecule therapies, and can improve tissue specificity and off-target toxicity. Orally bioavailable, PROTACs are not dependent on the occupancy-driven pharmacology inherent to inhibitory therapeutics, facilitating substoichiometric dosing that does not require an active or allosteric target binding site. Preliminary clinical data demonstrate promising therapeutic activity in heavily pretreated populations and novel technology platforms are poised to exploit a myriad of permutations of PROTAC molecular design to enhance efficacy and targeting specificity. As the field rapidly progresses and various non-PROTAC TPD drug candidates emerge, this review explores the scientific and preclinical foundations of PROTACs and presents them within common clinical contexts. Additionally, we examine the latest findings from ongoing active PROTAC clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsHumansProteolysisAllosteric SiteCytoplasmDrug Delivery SystemsProteasome Endopeptidase ComplexUbiquitin-Protein Ligases

Substanzen

Proteasome Endopeptidase ComplexUbiquitin-Protein Ligases

Autor:innen und Institutionen

  • Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.

ORCID-Profile: Joshua M L Casan, John F Seymour

Zitieren

APA

Casan, J. M. L., & Seymour, J. F. (2024). Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood. https://doi.org/10.1182/blood.2023022993

Vancouver

Casan JML, Seymour JF. Degraders upgraded: the rise of PROTACs in hematological malignancies. Blood. 2024. doi:10.1182/blood.2023022993

BibTeX
@article{Casan2024,
  author = {Casan, Joshua M L and Seymour, John F},
  title = {Degraders upgraded: the rise of PROTACs in hematological malignancies},
  journal = {Blood},
  year = {2024},
  doi = {10.1182/blood.2023022993}
}
Kostenlos starten →